OTCPK:GMDT.F

Stock Analysis Report

Executive Summary

Golden Meditech Holdings Limited, an investment holding company, operates as an integrated healthcare company in the People’s Republic of China.

Snowflake

Fundamentals

Flawless balance sheet and overvalued.

Share Price & News

How has Golden Meditech Holdings's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

0%

GMDT.F

4.6%

US Healthcare

2.3%

US Market


1 Year Return

-1.9%

GMDT.F

-8.5%

US Healthcare

5.6%

US Market

Return vs Industry: GMDT.F exceeded the US Healthcare industry which returned -8.5% over the past year.

Return vs Market: GMDT.F underperformed the US Market which returned 5.6% over the past year.


Shareholder returns

GMDT.FIndustryMarket
7 Day0%4.6%2.3%
30 Day1.0%-0.1%-1.0%
90 Day-13.7%-4.5%-0.7%
1 Year-1.9%-1.9%-7.1%-8.5%7.9%5.6%
3 Year-22.9%-22.9%31.9%26.5%45.6%36.3%
5 Year-36.9%-36.9%63.7%53.9%65.8%47.6%

Price Volatility Vs. Market

How volatile is Golden Meditech Holdings's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Golden Meditech Holdings undervalued compared to its fair value and its price relative to the market?

0.53x

Price to Book (PB) ratio


Share Price vs. Fair Value

Undervalued: Insufficient data to calculate GMDT.F's fair value to establish if it is undervalued.

Significantly Undervalued: Insufficient data to calculate GMDT.F's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: GMDT.F is unprofitable, so we can't compare its PE Ratio to the Healthcare industry average.

PE vs Market: GMDT.F is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

Low PEG Ratio: Insufficient data to calculate GMDT.F's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: GMDT.F is good value based on its PB Ratio (0.5x) compared to the US Healthcare industry average (2.5x).


Next Steps

Future Growth

How is Golden Meditech Holdings forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

10.8%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Golden Meditech Holdings has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

  • Examine Golden Meditech Holdings's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
  • While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on the OTC Markets Website. If you are looking for more of a qualitative research into the company, you can access Golden Meditech Holdings's filings and announcements here.
  • Explore growth companies in the Healthcare industry.

Past Performance

How has Golden Meditech Holdings performed over the past 5 years?

-1.5%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: GMDT.F is unprofitable, and losses have increased over the past 5 years at a rate of -1.5% per year.

Accelerating Growth: Unable to compare GMDT.F's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: GMDT.F is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare industry (5.3%).


Return on Equity

High ROE: GMDT.F has a negative Return on Equity (-15.86%), as it is currently unprofitable.


Return on Assets

ROA vs Industry: GMDT.F is currently unprofitable, so its Return on Assets is negative.


Return on Capital Employed

ROCE Improving: GMDT.F is currently unprofitable, so its Return on Capital Employed is negative.


Next Steps

Financial Health

How is Golden Meditech Holdings's financial position?


Financial Position Analysis

Short Term Liabilities: GMDT.F's short term assets (HK$3.9B) exceeds its short term liabilities (HK$2.8B)

Long Term Liabilities: GMDT.F's short term assets (3.9B) exceeds its long term liabilities (153.5M)


Debt to Equity History and Analysis

Debt Level: GMDT.F's debt to equity ratio (20.2%) is considered satisfactory

Reducing Debt: GMDT.F's debt to equity ratio has reduced from 27.7% to 20.2% over the past 5 years.


Balance Sheet

Inventory Level: GMDT.F has a high level of physical assets or inventory.

Debt Coverage by Assets: GMDT.F's debt is covered by short term assets (assets are 4.384050x debt).


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: GMDT.F has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: GMDT.F has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of -45.5% each year


Next Steps

Dividend

What is Golden Meditech Holdings's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

company0%marketbottom25%1.5%markettop25%3.8%industryaverage1.6%forecastin3Yearsn/a

Current dividend yield vs market & industry


Stability and Growth of Payments

Notable Dividend: Unable to evaluate GMDT.F's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate GMDT.F's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.

Stable Dividend: Insufficient data to determine if GMDT.F's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if GMDT.F's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: GMDT.F is not paying a notable dividend for the US market.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of GMDT.F's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

What is the CEO of Golden Meditech Holdings's salary, the management and board of directors tenure and is there insider trading?

0.4yrs

Average board tenure


CEO

Kim Leong (49yo)

0.4yrs

Tenure

0

Mr. Kim Chuan Leong serves as Chief Executive Officer, Compliance Officer and Executive Director of Golden Meditech Holdings Limited since May 24, 2019. He serves as Deputy Chief Financial Officer at Golde ...


Board Age and Tenure

0.4yrs

Average Tenure

44.5yo

Average Age

Experienced Board: GMDT.F's board of directors are not considered experienced ( 0.4 years average tenure), which suggests a new board.


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

SellHK$113,05926 Apr 19
Atlantis Investment Management (Ireland) Limited
EntityCompany
Shares1,112,000
Max PriceHK$0.10

Ownership Breakdown


Management Team

  • Dao Pei Lu (87yo)

    President of Shanghai Dao Pei Hospital

    • Tenure: 0yrs
  • Zu Qin Lai (80yo)

    Chief Scientist of Qijieyuan and Inventor of TangHerb

    • Tenure: 0yrs
  • Bao Shao (53yo)

    Chief Executive Officer of the Chinese Herbal Medicine Operation

    • Tenure: 0yrs
  • Jian Zhong Jing (65yo)

    VP & Chief Representative of Shanghai Office

    • Tenure: 0yrs
  • Wei Ding (70yo)

    Chief Executive Officer of GM Medicare Management (China) Company Limited

    • Tenure: 0yrs
  • Wen Feng (51yo)

    Chairman of the Board

    • Tenure: 0.4yrs
    • Compensation: HK$2.47m
  • Fan Huang (45yo)

    Chief Executive Officer of Medical Devices Operation

    • Tenure: 0yrs
  • Kim Leong (49yo)

    CEO, Deputy CFO

    • Tenure: 0.4yrs
  • Joanna Rui

    Investor Relations Manager

    • Tenure: 0yrs
  • Cheuk Man Lam

    Company Secretary

    • Tenure: 0.4yrs

Board Members

  • Xue Tao Pei

    Member of Technology Development Advisory Board

    • Tenure: 0yrs
  • Ming Tian

    Member of Technology Development Advisory Board

    • Tenure: 0yrs
  • Bao Guo Wang

    Member of Technology Development Advisory Board

    • Tenure: 0yrs
  • Ming Li Zhang

    Chairman of Technology Development Advisory Board

    • Tenure: 0yrs
  • Albert Chen (43yo)

    CFO & Executive Director of China Cord Blood Corporation

    • Tenure: 0yrs
  • Wen Feng (51yo)

    Chairman of the Board

    • Tenure: 0.4yrs
    • Compensation: HK$2.47m
  • Yue Gao (46yo)

    Independent Non Executive Director

    • Tenure: 4.9yrs
    • Compensation: HK$460.00k
  • Daniel Foa (42yo)

    Independent Non-Executive Director

    • Tenure: 4.7yrs
    • Compensation: HK$600.00k
  • Kim Leong (49yo)

    CEO, Deputy CFO

    • Tenure: 0.4yrs
  • Poon Hang (41yo)

    Independent Non-Executive Director

    • Tenure: 0.4yrs

Company Information

Golden Meditech Holdings Limited's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Golden Meditech Holdings Limited
  • Ticker: GMDT.F
  • Exchange: OTCPK
  • Founded: 2001
  • Industry: Health Care Services
  • Sector: Healthcare
  • Market Cap: HK$2.334b
  • Listing Market Cap: HK$297.462m
  • Shares outstanding: 2.92b
  • Website: https://www.goldenmeditech.com

Number of Employees


Location

  • Golden Meditech Holdings Limited
  • No. 11 Wan Yuan Street
  • Beijing Economic Technological Development Area
  • Beijing
  • 100176
  • China

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
GMDT.FOTCPK (Pink Sheets LLC)YesOrdinary SharesUSUSDDec 2001
801SEHK (The Stock Exchange of Hong Kong Ltd.)YesOrdinary SharesHKHKDDec 2001

Biography

Golden Meditech Holdings Limited, an investment holding company, operates as an integrated healthcare company in the People’s Republic of China. It operates in five segments: Medical Devices, Hospital Busi ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/16 23:51
End of Day Share Price2019/09/25 00:00
Earnings2019/03/31
Annual Earnings2019/03/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.